BiotechTube
Strata Oncology

Strata Oncology

Ann Arbor, United States· Est.
strataoncology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

Strata Oncology is a private, commercial-stage diagnostics company founded in 2016 and headquartered in Ann Arbor, Michigan. It has developed a proprietary precision oncology platform that generates multivariate biomarker scores, notably the Immunotherapy Response Score (IRS) and the Antibody-Drug Conjugate Treatment Response Score (ADC TRS), to predict patient benefit from specific cancer therapies. The company's model is based on providing diagnostic testing services and partnering with biopharma companies, positioning it at the intersection of AI-driven diagnostics and clinical decision support in oncology. Its growth is supported by recognized investors and a focus on expanding the clinical utility of its innovative biomarkers.

Oncology

Technology Platform

Proprietary precision oncology platform using AI/ML algorithms to generate multivariate predictive biomarker scores from tumor sequencing and digital pathology data. Core products include the Immunotherapy Response Score (IRS) and Antibody-Drug Conjugate Treatment Response Score (ADC TRS).

Funding History

3
Total raised:$40M
Series B$26M
Series A$12M
Seed$2M

Opportunities

The rapid expansion of ADC and immunotherapy markets creates a pressing need for better predictive biomarkers.
Strata can capitalize by partnering with pharma companies to develop companion diagnostics and by offering its tests as a service to oncologists seeking to optimize treatment selection.
Its algorithmic approach could become a standard tool in clinical trials and routine care.

Risk Factors

Key risks include the need for extensive ongoing clinical validation to achieve widespread adoption, intense competition from larger diagnostic firms, and challenges in securing consistent insurance reimbursement for novel tests.
The performance of its complex algorithms must be robust across diverse real-world patient populations.

Competitive Landscape

Strata competes in the crowded precision oncology diagnostics market against large, integrated players like Foundation Medicine (Roche) and Guardant Health, which offer broad NGS panels and have established reimbursement. Its differentiation lies in its proprietary multivariate algorithms (IRS, ADC TRS) rather than just comprehensive genomic profiling, positioning it as a specialist in predictive biomarker scores for specific therapy classes.

More companies in Oncology (General) →More companies in United States →